FOXO4-DRI
Preclinical ResearchFOXO4-DRI
A senolytic peptide designed to selectively trigger apoptosis in senescent (zombie) cells. Researched as a potential anti-aging intervention.
Dose
Research protocols commonly discuss doses in ranges, for example, 1-5 mg per administration.
Route
SubQ injection
Cycle
Research protocols often involve cycles of 3-7 days of administration.
Storage
Lyophilized powder is commonly stored refrigerated at 2-8°C (36-46°F) away from light.
What is FOXO4-DRI?
FOXO4-DRI is a synthetic peptide designed to selectively target and induce apoptosis in senescent cells. It functions by disrupting the interaction between FOXO4 and p53, a critical pathway involved in the survival of senescent cells. By preventing FOXO4 from sequestering p53, the peptide allows p53 to activate pro-apoptotic genes, leading to the programmed cell death of 'zombie' cells. This mechanism is thought to spare healthy, non-senescent cells, making it a subject of significant interest in anti-aging research and potential therapeutic applications for age-related conditions.
Key Benefits
- Senescent cell clearance
- Potential tissue rejuvenation
- Anti-aging research
- FOXO4-p53 pathway disruption
Mechanism of Action
- Disrupts FOXO4-p53 protein interaction in senescent cells
- Triggers apoptosis specifically in zombie cells
- Spares healthy cells
Best For
- Advanced longevity research
- Senolytic research
- Anti-aging
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
1910.2 g/mol
Length
12 amino acids
Type
Peptide
Amino acid sequence
H-L-T-L-P-P-V-S-D-F-K-F
H (Histidine), L (Leucine), T (Threonine), P (Proline), V (Valine), S (Serine), D (Aspartic Acid), F (Phenylalanine), K (Lysine)
Research Indications
Senescent Cell Clearance
FOXO4-DRI is primarily researched for its ability to selectively induce apoptosis in senescent cells, which accumulate with age and contribute to various age-related pathologies.
Potential Tissue Rejuvenation
By removing senescent cells, research suggests FOXO4-DRI may facilitate the regeneration of healthy tissues and improve function in aged organisms.
Impact on Age-Related Dysfunction
Studies explore its potential to ameliorate phenotypes associated with aging, such as impaired physical function, metabolic dysfunction, and cognitive decline in animal models.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute Senescent Cell Clearance (e.g., in animal models of accelerated aging) | 1-5 mg/kg | Once every 3-7 days for a single cycle | Subcutaneous injection |
| Long-Term Anti-Aging Intervention (e.g., in aged animal models) | 1-3 mg/kg | Once weekly for 3 weeks, followed by an 8-week break, repeated for multiple cycles | Subcutaneous injection |
| Targeting Localized Senescence (e.g., specific organ studies) | Dose adjusted based on tissue mass, e.g., 0.5-2 mg/kg | Administered 2-3 times over a 1-week period | Subcutaneous injection |
| Investigating Metabolic Effects | 2-4 mg/kg | Once every 5 days for 2-3 cycles, with 4-week breaks | Subcutaneous injection |
| Evaluation of Musculoskeletal Benefits | 1.5-3 mg/kg | Twice weekly for 2 weeks, followed by a 4-week observation period | Subcutaneous injection |
Research protocols emphasize cyclical administration rather than daily, continuous use, to allow for clearance of senescent cells and recovery periods.
Peptide Interactions
- Monitor Combination
Dasatinib and Quercetin (D+Q)
D+Q is another well-known senolytic combination. While FOXO4-DRI targets a distinct pathway, combining different senolytics is an area of active research. Monitoring for additive or synergistic effects, as well as potential increased side effects, is crucial.
- Compatible
Metformin
Metformin has some senomorphic properties (inhibiting senescent cell functions) rather than senolytic. No known direct adverse interactions with FOXO4-DRI are reported, and they could potentially act complementarily.
- Compatible
Rapamycin
Rapamycin modulates mTOR pathways and has anti-aging effects distinct from senolysis. No reported adverse interactions with FOXO4-DRI, suggesting potential for combined research.
- Use Caution
Corticosteroids
Corticosteroids can influence cellular processes including apoptosis and inflammation. Their interaction with senolytic agents like FOXO4-DRI has not been extensively studied; caution is advised due to potential unknown effects on cellular pathways.
- Use Caution
Immunosuppressants
Since FOXO4-DRI impacts cellular turnover and immune response related to senescent cells, combining it with immunosuppressants could have complex and unstudied effects on immune function. Close monitoring is recommended.
- Avoid
Chemotherapeutic Agents
Chemotherapeutic agents often induce cellular stress and can sometimes induce senescence. The combination with a senolytic peptide could lead to unpredictable or counterproductive outcomes, and is generally avoided in research unless specifically designed for oncology studies.
How to Reconstitute
- 1Gather necessary supplies: FOXO4-DRI vial, bacteriostatic water for injection (BW), sterile syringes (e.g., 1mL), sterile needles (e.g., 23-30 gauge), alcohol swabs.
- 2Clean the rubber stopper of the FOXO4-DRI vial and the BW vial with alcohol swabs.
- 3Draw the desired amount of BW into a sterile syringe. Common reconstitution ratios aim for a manageable concentration (e.g., 1mg/mL).
- 4Slowly inject the BW into the FOXO4-DRI vial, aiming the stream at the side of the glass to avoid direct impact on the lyophilized powder.
- 5Do not shake the vial. Gently swirl the vial to facilitate dissolution of the powder. If necessary, allow it to sit in a refrigerator for a short period to fully dissolve.
- 6Once fully dissolved, the solution should be clear and free of particulate matter. Store reconstituted peptide according to guidelines.
Reconstitution should be performed under sterile conditions. The choice of diluent is critical for peptide stability and integrity.
What to Expect
- Weeks 1-2: Initial senescent cell clearance may begin, but no immediate or dramatic observable changes are commonly reported.
- Weeks 3-4: Continued senescent cell reduction in targeted tissues may be occurring, potentially associated with subtle improvements in energy or tissue function in animal models.
- Months 1-3 (post-cycle): Some research suggests longer-term benefits emerging, such as improvements in various physiological markers or tissue regenerative capacities.
- Months 3-6+: Sustained benefits or a need for subsequent cycles may be explored depending on research goals and observed outcomes.
- Variability: Individual responses in research subjects can vary widely based on baseline senescent cell burden, age, and health status.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Unknown long-term profile | Unknown | Unknown |
| Potential inflammatory response as senescent cells clear | Theoretical | Mild-Moderate |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.